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OBJECTIVES: EGFR testing and first line gefitinib for patients with activating mu-
tations is quickly becoming a standard option for the treatment of advanced Non-
Small Cell Lung Cancer. Yet, little is known about the cost-effectiveness of this
approach. METHODS: A decision-analytic model was developed to determine the
cost effectiveness of EGFR mutation testing and first line treatment with gefitinib
guided by the results vs. standard care with first line chemotherapy followed by
gefitinib as second line treatment in unselected patients. Further analyses as-
sessed 1st line gefitinib vs. chemotherapy in patients with activating EGFR muta-
tions and 1st line gefitinib for patients with EGFRmutations vs. no EGFR testing and
chemotherapy only as the standard arm. The model uses clinical and outcomes
data from randomized clinical trials and societal costs from cancer centers in Sin-
gapore. Costs include relevant costs for medications, physician visits, laboratory
tests, scans, hospitalizations and treatment of adverse events. All costs and cost-
effectiveness ratios were expressed in 2010 Singapore Dollars. Sensitivity analyses
were conducted. RESULTS: EGFR testing and first line treatment with gefitinib was
a dominant strategy compared to no testing followed by 1st line chemotherapy and
2nd line gefitinib in unselected patients. The primary savings in the testing arm
result from not providing gefitinib to those who do not benefit. First line treatment
with gefitinib was also dominant when compared to first line chemotherapy in
patients with activating EGFRmutations, mainly due to an improvement in quality
of life. Treatmentwith gefitinib for patients withmutations (and chemotherapy for
those without) was associated with a base-case incremental cost effectiveness
ratio below SGD 80,000/QALY vs. chemotherapy only. (1.3 SGD  1 USD)
CONCLUSIONS: Based on these data, EGFR testing and first line treatment with
gefitinib for patients with activating mutations is a standard option in the treat-
ment of advanced NSLC.
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OBJECTIVES: Leuprolide is one of the most common LH-RH agonists used in ad-
vanced prostate cancer. An economic study was conducted to assess which of the
existing leuprolide formulations are more cost-effective for the management of
prostate cancer in Belgium.METHODS:Major database searches identified clinical
trials of leuprolide 1- (1M), 3- (3M) and 6-monthly (6M); no differences in efficacy
and safety were found. We conducted cost-minimisation analysis using an Excel
model. Adherence and safety were not significantly different; costs of leuprolide,
specialist consultations and diagnostics were considered during up to 12 months
follow-up. Costs were available for 2009, not discounted due to short time horizon.
The perspective was that of the public payer: RIZIV/NAMI. RESULTS: 1M was the
most expensive treatment at 3,746€. The 3M formulationwas 1,739€ less costly and
6M offered cost-savings of 2,126€ compared to 1M and 387€ versus 3M. Cost of
leuprolide was also the highest for 1M: 1,628€; 3M cost 1,117€ and 6M 1,097€. Total
costs were associated with the frequency of visits for injection andmonitoring. 1M
required 12 visits, 3M 4.4 visits, and 6M 2.1 visits. 36.7% [95%CI: 34.7-38.5%] addi-
tional visits could be funded with the savings resulting from switching eligible
patients from 1M and 3M to 6M. Results were stable in one-way sensitivity analy-
ses. In the probabilistic sensitivity analysis the 95% uncertainty intervals for total
costs were 3,497-4,019€, 1,802-2,000€ and 1,429-1,519€ for 1M, 3M and 6M,
respectively. CONCLUSIONS: The 6-monthly formulation offers the greatest cost-
savings in Belgium.
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OBJECTIVES: Leuprolide is one of the most common LH-RH agonist used in ad-
vanced prostate cancer. An economic evaluationwas conducted to assess which of
leuprolide formulations are more cost-effective for the management of prostate
cancer in Portugal.METHODS:Major database searches identified clinical trials of
leuprolide 1- (1M), 3- (3M) and 6-monthly (6M); no differences in efficacy and safety
were found. We conducted cost-minimisation analysis using an Excel model. Ad-
herence and safety were not significantly different; costs of leuprolide, specialist
consultations and diagnostics were considered during up to 12 months follow-up.
Costs were not discounted due to short time horizon. The perspective was that of
the public payer: Serviço Nacional de Saúde. RESULTS: 1Mwas themost expensive
treatment at 4,597€. The 3M formulation was 11,788€ less costly and 6M offered
cost-savings of 2,230€ compared to 1M and 387€ versus 3M. Cost of leuprolide was
also the highest for 1M: 1,812€; 3M cost 1,617€ and 6M 1,728€. Total costs were
associatedwith the frequency of visits for injection andmonitoring. 1M required 12
visits, 3M 4.8 visits, and 6M 2.3 visits. 14.7% [95%CI:12.4-17.5%] additional visits
could be funded with the savings resulting from switching eligible patients from
1M and 3M to 6M. Results were stable in one-way sensitivity analyses. In the prob-
abilistic sensitivity analysis the 95% uncertainty intervals for total costs were
4,219-4,907€, 2,578-2,874€ and 2,189-2,323€ for 1M, 3M and 6M, respectively.
CONCLUSIONS: The 6-monthly formulation offers the greatest cost-savings in Portu-
gal.
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OBJECTIVES: It was sought to demonstrate that the use of rasburicase to treat
tumor lysis syndrome (TLS) associated with chemotherapy in children with acute
leukemia or high grade lymphomas, could prove not only more effective and safer
compared to conventional treatment (allopurinol and urine alkalinization), but
also less expensive.METHODS: The authors conducted a cost minimization anal-
ysis under the SUS perspective, using retrospective data regarding childrens with
TSL whose hyperuricemia was treated with rasburicase, from a Phase IV clinical
trial conducted in the IOP / GRAACC / UNIFESP in year 2006-07 (Group 1). In the
control group the children included were selected by using the same set of criteria,
assisted into the same institution during the period 2007-8, which received con-
ventional treatment with allopurinol and alkalinization (Group 2). The clinical and
economic data were processed and analyzed comparatively. RESULTS: The main
crude economic results showed that patients in Group 1 (rasburicase) had higher
costs (R$ 11,898.58) compared with Group 2 (R$ 5,887.40), but most of these costs
(77%) was due to the large use of rasburicase as had been previously defined by
protocol (7 days), despite the fact of uricemia had been normalized on the second
day of treatment. Considering this demonstration of clinical benefit, supported by
publicationswhich comproved benefits on usingminimal doses of rasburicase, the
authors were able to perform simulations that show that the cost of treat TSL with
rasburicase may imply in costs 50% lower than those observed in Group 2 (treat-
ment conservative), with the advantage of normalizing the serumuric acid levels in
just two days. CONCLUSIONS: The use of rasburicase is a valid option to reduce the
costs of treating TLS in pediatric oncology, in relation to the conservative alterna-
tive, with major benefits for patients.
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OBJECTIVES: To assess the potential outcomes of ERCC1 expression testing to in-
form adjuvant chemotherapy decisions in fully resected Stage I non-small cell lung
cancer (NSCLC) from a U.S. societal perspective.METHODS:We developed a deci-
sion analyticmodel to estimate directmedical costs andquality-adjusted life-years
(QALYs) for two treatment strategies: 1) ERCC1 testing to inform adjuvant chemo-
therapy decisions, with ERCC1 patients receiving no chemotherapy, and ERCC1-
patients receiving chemotherapy; 2) standard care, with all patients receiving no
chemotherapy.We derived clinical parameters from a retrospective analysis of the
International Adjuvant Lung Cancer Trial, published literature, and government
sources. We included trial-based adverse events and costs related to drug treat-
ment, routine follow-up, AEs, and post-progression care. We conducted one-way
and probabilistic sensitivity analyses (PSA) to examine uncertainty. RESULTS:
QALYs for the ERCC1 and standard care strategies were 4.42 and 4.34, respectively.
Total costs were $28,800 and $25,500, respectively. Relative to the standard care
strategy, the ERCC1 strategy had an incremental cost-effectiveness ratio (ICER) of
$43,266 per QALY gained. Incremental costs and QALYs were sensitive to overall
survival in ERCC1 strategy patients, distant recurrence free survival for both strat-
egies, and proportion of patients testing ERCC1. In the PSA, the ICER was highly
variable, with a 95% credible range of dominated to $553,184/QALY. The standard
care strategy was optimal until a willingness-to-pay of $25,000 per QALY, after
which the ERCC1 strategy was optimal. CONCLUSIONS: Compared to standard
care, ERCC1 expression testing has the potential to improve patient outcomes in a
cost-effective manner. However, our findings are limited by highly variable incre-
mental outcomes due to high levels of uncertainty in overall and disease-free
survival parameters. Overall, ERCC1 testing holds great promise as a predictive tool
to guide adjuvant chemotherapy decisions in Stage I NSCLC, but additional
evidence is needed before clinical guidelines and reimbursement policies can be
formulated.
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OBJECTIVES: Chronic myelogenous leukaemia (CML) is a progressive disease asso-
ciated with significant health and economic burden. This study estimates lifetime
costs and health outcomes associated with dasatinib treatment for chronic-phase
imatinib-resistant CML patients. METHODS: A Markov model was developed to
estimate lifetime costs and health outcomes associatedwith the treatment of ima-
tinib-resistant CML patients. Seven treatments were modelled: (i) dasatinib100mg,
(ii) imatinib 400mg, (iii) imatinib 600mg, (iv) imatinib 800mg, (v) nilotinib, (vi) inter-
feron-a, (vii) bone marrow transplant (BMT). Five initial best response rate catego-
ries were defined: no response, complete haematologic, partial cytogenetic, com-
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